Double-Drug attack on stubborn IBD shows promise
NCT ID NCT07660289
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether using two advanced drugs together (either two biologics or one biologic plus a small molecule) is safe and effective for people with inflammatory bowel disease (IBD) who haven't gotten better on standard treatments. Researchers followed 117 patients in China, tracking their symptoms, endoscopic healing, and side effects. The goal was to see if this dual approach could improve outcomes in real-world practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- combination of two biologic agents or one biologic plus one small molecule drug
- What this could lead to
- If successful, this could point toward a more effective treatment option for people with inflammatory bowel disease that hasn't responded to standard therapies.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. The combination therapies also carry higher risks of side effects like infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMBINATION THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Xijing Hosipital of Digestive Disease
Xi'an, Shaanxi, 710005, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sleep hormone melatonin put to the test for IBD patients with poor sleep
- Which diet do IBD patients prefer? intermittent fasting, mediterranean, or low FODMAP?
- Could a metabolic modulator help people with type 1 diabetes use insulin better?
- Could a postbiotic soothe irritable bowel syndrome?
- Podcast vs. pamphlet: which boosts IBD knowledge best?
- New oral drug for inflammatory bowel disease enters first human tests